| Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment M Sandström, U Garske-Román, D Granberg, S Johansson, C Widström, ... Journal of Nuclear Medicine 54 (1), 33-41, 2013 | 275 | 2013 |
| Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule V Tolmachev, A Orlova, R Pehrson, J Galli, B Baastrup, K Andersson, ... Cancer research 67 (6), 2773-2782, 2007 | 274 | 2007 |
| First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule J Sörensen, D Sandberg, M Sandström, A Wennborg, J Feldwisch, ... Journal of nuclear medicine 55 (5), 730-735, 2014 | 266 | 2014 |
| Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT J Sörensen, I Velikyan, D Sandberg, A Wennborg, J Feldwisch, ... Theranostics 6 (2), 262, 2016 | 252 | 2016 |
| Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors A Orlova, V Tolmachev, R Pehrson, M Lindborg, T Tran, M Sandstrom, ... Cancer research 67 (5), 2178-2186, 2007 | 237 | 2007 |
| Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and … U Garske-Román, M Sandström, K Fröss Baron, L Lundin, P Hellman, ... European journal of nuclear medicine and molecular imaging 45, 970-988, 2018 | 236 | 2018 |
| Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE E Ilan, M Sandström, C Wassberg, A Sundin, U Garske–Román, ... Journal of nuclear medicine 56 (2), 177-182, 2015 | 226 | 2015 |
| Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate M Sandström, U Garske, D Granberg, A Sundin, H Lundqvist European journal of nuclear medicine and molecular imaging 37, 212-225, 2010 | 197 | 2010 |
| Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification I Velikyan, A Sundin, J Sörensen, M Lubberink, M Sandström, ... Journal of Nuclear Medicine 55 (2), 204-210, 2014 | 191 | 2014 |
| Regional lung perfusion estimated by electrical impedance tomography in a piglet model of lung collapse JB Borges, F Suarez-Sipmann, SH Bohm, G Tusman, A Melo, E Maripuu, ... Journal of applied physiology 112 (1), 225-236, 2012 | 189 | 2012 |
| Regional lung perfusion estimated by electrical impedance tomography in a piglet model of lung collapse JB Borges, F Suarez-Sipmann, SH Bohm, G Tusman, A Melo, E Maripuu, ... Journal of applied physiology 112 (1), 225-236, 2012 | 189 | 2012 |
| Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors M Sandström, I Velikyan, U Garske-Román, J Sörensen, B Eriksson, ... Journal of Nuclear Medicine 54 (10), 1755-1759, 2013 | 163 | 2013 |
| Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry V Tolmachev, M Friedman, M Sandström, TLJ Eriksson, D Rosik, M Hodik, ... Journal of Nuclear Medicine 50 (2), 274-283, 2009 | 147 | 2009 |
| Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected … V Tolmachev, D Rosik, H Wållberg, A Sjöberg, M Sandström, M Hansson, ... European journal of nuclear medicine and molecular imaging 37, 613-622, 2010 | 143 | 2010 |
| 99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors T Tran, T Engfeldt, A Orlova, M Sandström, J Feldwisch, L Abrahmsén, ... Bioconjugate chemistry 18 (6), 1956-1964, 2007 | 139 | 2007 |
| Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules S Ahlgren, A Orlova, D Rosik, M Sandström, A Sjöberg, B Baastrup, ... Bioconjugate chemistry 19 (1), 235-243, 2008 | 137 | 2008 |
| Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients M Sandström, K Lindskog, I Velikyan, A Wennborg, J Feldwisch, ... Journal of Nuclear Medicine 57 (6), 867-871, 2016 | 119 | 2016 |
| Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold S Ahlgren, A Orlova, H Wållberg, M Hansson, M Sandström, R Lewsley, ... Journal of nuclear medicine 51 (7), 1131-1138, 2010 | 119 | 2010 |
| A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue V Tolmachev, I Velikyan, M Sandström, A Orlova European journal of nuclear medicine and molecular imaging 37, 1356-1367, 2010 | 101 | 2010 |
| Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force C Stokke, PM Gabiña, P Solný, F Cicone, M Sandström, KS Gleisner, ... EJNMMI physics 4, 1-9, 2017 | 95 | 2017 |
